

Montigny-le-Bretonneux, November 16th 2016

## Bertin Pharma and INDIGO Biosciences sign agreement for distributing Nuclear Receptor Assay kits in Europe

**Nuclear Receptor Assay kits now available in Europe for Discovery and Toxicology dedicated to over 20 Disease States such as Cardiovascular Disease, Metabolic Disease, or even Endocrinology**

INDIGO Biosciences, recognised as a leader in Nuclear Receptor Research, provides the world's largest portfolio of Nuclear Receptor Assay kits. Those kits are all-inclusive, cell-based, robust, and ready to use for 3x 32, 96, and 384 formats. With a fast-growing business in the USA, INDIGO Biosciences wishes to benefit from increased European exposure to capture new market shares.

Bertin Pharma is one of the major European players for the supply of reagents and assay kits dedicated to the research and development for the pharmaceutical, cosmetic and food industries. Bertin Pharma has marketed biological reagent ranges for over 25 years. Its long R&D experience combined with its International distributor channels enable to deliver life science tools on time and to support customers throughout their experimentation.

INDIGO and Bertin Pharma have signed a distribution agreement to highlight this unique range of Nuclear Receptor Assay kits through its European distribution network.

Bertin Pharma completes, with this new range of Nuclear Receptor Assay kits, its existing ranges of biomarker assays applied to his expertise areas that are metabolic syndrome, hypertension or even oncology.

*"It has been a real honor to be introduced to Fred and his company and we rapidly found a lot of complementarity in our business. The Nuclear Assay range perfectly fit with our customer's needs, and will empower our commercial activity."* Said Patrick Vitaux, Bioreagent Dpt Manager – Bertin Pharma

*"We are pleased to have reached an agreement with Bertin Pharma to expand our distribution network in Europe. We look forward to working with Patrick and his team to bring INDIGO's assay portfolio to their customers throughout the region."* Fred Marroni, CEO – INDIGO Biosciences

### About INDIGO Biosciences

INDIGO Biosciences, Inc. was founded in 2005 in State College, PA. It remains a privately held biosciences company offering products and services focused on nuclear receptors to the Pharmaceutical, Biotechnology, Environmental and Nutraceutical market. INDIGO provides high-quality, confidential screening services and assay kits for drug discovery and toxicology research.

For further information visit [www.indigobiosciences.com](http://www.indigobiosciences.com)

### Contact INDIGO Biosciences

Fred Marroni (814)234-1919  
[fred@indigobiosciences.com](mailto:fred@indigobiosciences.com)

## About Bertin Pharma

Bertin Pharma, subsidiary of Bertin Technologies (Group CNIM), is a European R&D pharmaceutical leading player. It offers both expertise as services and bioanalytical tools

Backed by more than 20 years of experience in the development and validation of endogenous and exogenous biomarkers assays, Bertin Pharma has developed more than 150 assays. Its comprehensive offer covers number of therapeutic areas such as hypertension, diabetes, obesity, psychopharmacology, inflammation, growth hormone, oncology, allergy, etc.

Thanks to the multidisciplinary and complementary know-how of its scientists, Bertin Pharma can advise you before, during and after your experimentation.

Bertin Pharma distributes its high quality products worldwide thanks to our distribution platform and our international distribution network.

Bertin Pharma benefits from a loyal and prestigious client base: Big & Mid Pharma, biotech Companies and also public research laboratories.

For further information, visit [www.bertinpharma.com](http://www.bertinpharma.com).

### ► **CONTACTS PRESS Bertin Pharma**

#### **Agence Gootenberg**

Laurence Colin / Frédérique Vigezzi, +33 (0)143 59 2984  
[cnim@gootenberg.fr](mailto:cnim@gootenberg.fr)

#### **Bertin Pharma**

Florence Fombertasse, +33 (0)139 306 225  
[Florence.fombertasse@bertinpharma.com](mailto:Florence.fombertasse@bertinpharma.com)

## About Bertin Technologies

Bertin Technologies, a subsidiary of CNIM, relies on its historical experience of innovative engineering to develop, produce and market worldwide innovative systems and equipment:

- advice, studies and expertise
- development of processes, pilots and prototypes
- design and supply of software and high-value equipment

Its 500 engineers and top scientists allow it to intervene in particular in the areas of energy and environment, defense and security, pharmaceuticals and life sciences, or aerospace.

Based in Montigny-le-Bretonneux, nearby Paris, the Group is also present in Orléans, in the Southwest and in the Southeast of France. It is very active internationally, notably through its subsidiary Bertin Corp. based in Washington.

Please visit [WWW.BERTIN-TECHNOLOGIES.COM/INDEX.ASPX](http://WWW.BERTIN-TECHNOLOGIES.COM/INDEX.ASPX)

### ► **CONTACTS PRESS Bertin Technologies**

#### **Agence Gootenberg**

Laurence Colin / Frédérique Vigezzi, +33 (0)143 59 2984

[cnim@gootenberg.fr](mailto:cnim@gootenberg.fr)

#### **Bertin Technologies**

Juliette Duault, +33 (0)144 311 194  
+33 (0)607 109 344  
[Juliette.duault@cnim.fr](mailto:Juliette.duault@cnim.fr)

#### AT A GLANCE

- 2015 turnover: 15.5 M€
- Customers: Pharmaceutical Laboratories, Public Research Laboratories, Contract research, players in the field of Cosmetics and Food Industries.
- Head office located in Montigny-Le-Bretonneux (Paris region)
- > 120 collaborators managed by experts and highly qualified management
- 6 brands/ranges of products including 2 proprietaries (SPI-Bio & MS2Plex)